Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 13/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25546198 | 0.92 | FBP1 (0.41) | AAK1FBP1CYP3A4S1PR1XDH | |
| SCHEMBL25545528 | 0.86 | FBP1 (0.43) | AAK1FBP1ALDH1A1HPGDHTT | |
| SCHEMBL25545990 | 0.84 | FBP1 (0.42) | AAK1FBP1ALDH1A1HPGDHTT | |
| SCHEMBL25545566 | 0.84 | FBP1 (0.43) | FBP1S1PR1ALDH1A1HPGDHTT | |
| SCHEMBL25183737 | 0.84 | FBP1 (0.45) | FBP1ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL25545551 | 0.81 | FBP1 (0.43) | AAK1FBP1ALDH1A1 | |
| SCHEMBL25545555 | 0.81 | FBP1 (0.44) | AAK1FBP1CYP3A4XDHHPGD | |
| SCHEMBL25546044 | 0.80 | FBP1 (0.41) | AAK1FBP1CYP3A4XDHAR | |
| SCHEMBL25551705 | 0.79 | FBP1 (0.43) | FBP1HTT | |
| SCHEMBL25545539 | 0.79 | FBP1 (0.48) | FBP1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | AAK1 1064/4885FBP1 735/4885CYP3A4 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.